Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Dhawale A"'
Autor:
P. Connor Connor Johnson, Tejaswini M. Dhawale, Richard A. Newcomb, Hermioni L. Amonoo, Mitchell W. Lavoie, Dagny M. Vaughn, Kyle Karpinski, Areej El-Jawahri
Publikováno v:
Blood Advances.
CAR-T cell therapy has transformed treatment for relapsed/refractory hematologic malignancies but has complex logistics and unique toxicities. Data examining the patient-reported outcomes (PROs) of CAR-T recipients are limited. We conducted a longitu
Autor:
Tejaswini Dhawale, P. Connor Johnson, Mahmoud R. Gaballa, Ashley Nelson, Mitchell W. Lavoie, Matthew Frigault, Kofi Boateng, Claire Greydanus, Areej El-Jawahri
Publikováno v:
Blood. 140:10989-10990
Autor:
Patrick Connor Johnson, Tejaswini Dhawale, Mitchell W. Lavoie, Kyle Karpinski, Netana H. Markovitz, Kathleen Hennessey, Matthew Frigault, Areej El-Jawahri
Publikováno v:
Blood. 140:5232-5233
Autor:
Ashley M. Nelson, Thomas W. LeBlanc, Lauren Goldschen, Hermioni L. Amonoo, Andrew M. Brunner, Daniel Yang, Lauren Heuer, Areej El-Jawahri, Monica Bodd, P. Connor Johnson, Richard Newcomb, Elizabeth Daskalakis, Sabah Gillani, Amir T. Fathi, Tejaswini Dhawale, Matthew J. Reynolds, Emma C. Deary
Publikováno v:
Blood. 138:4131-4131
Background: Patients with acute myeloid leukemia (AML) who receive intensive chemotherapy must cope with immense physical and psychological symptoms associated with a variety of patient-reported outcomes (PROs) such as quality of life (QOL). Although
Autor:
Sioban Keel, Megan Othus, Vivian G. Oehler, Elihu H. Estey, Tejaswini Dhawale, Paul C. Hendrie, Kelda M. Gardner, Janis L. Abkowitz, Anna B. Halpern, Bart L. Scott, Roland B. Walter, Kaysey F. Orlowski, Pamela S. Becker, Colin D. Godwin, Alice Woo, Mary-Elizabeth M. Percival
Publikováno v:
Blood. 134:3892-3892
Background: We recently found that CLAG-M was safe and produced higher rates of CR/CRi and higher measurable residual disease (MRD)-negative CR (measured by multiparameter flow cytometry [MFC]) than standard "7+3" therapy in fit patients with newly-d
Autor:
Aude G. Chapuis, Tejaswini Dhawale, Utkarsh Acharya, Aesha Vakil, Brian G. Till, Cameron J. Turtle, Daniel Li, Jorge Ramos, Barbara S. Pender, Alexandre V. Hirayama, Reed M. Hawkins, Paul C. Hendrie, Hans-Peter Kiem, Stanley R. Riddell, Rachel N. Steinmetz, Kevin A. Hay, Tinh-Doan Phi, David G. Maloney, Ryan D. Cassaday, Jordan Gauthier, James Lymp, Mazyar Shadman, Alyssa Sheih, Janaki Purushe
Publikováno v:
Blood. 132:299-299
Background We reported durable responses to CD19-specific chimeric antigen receptor-modified T-cell therapy (JCAR014) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients (pts) after prior failure of ibrutinib (Turtle, JCO 2017; N
Autor:
Tejaswini Dhawale
Publikováno v:
The Hematologist. 12